1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B2147
    2-Aminobenzenesulfonamide
    Inhibitor 99.90%
    2-Aminobenzenesulfonamide is a carbonic anhydrase IX inhibitor.
    2-Aminobenzenesulfonamide
  • HY-B1471
    Fluorometholone acetate
    Inhibitor 98.54%
    Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonic anhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research.
    Fluorometholone acetate
  • HY-P1775
    Carbonic anhydrase, Bovine erythrocytes
    Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.

    Carbonic anhydrase, Bovine erythrocytes
  • HY-77036
    Furagin
    Inhibitor 99.84%
    Furagin (Furazidine), an analogue of Nitrofurantoin (HY-A0090), is an antibiotic with antibacterial activity against ESKAPE pathogens with MIC values of 0-32 µg/mL. Furagin inhibits human Carbonic anhydrases . Furagin is promising for research of cancer and urinary tract infections (UTIs).
    Furagin
  • HY-B1386
    Halazone
    Inhibitor
    Halazone is an atypical antimicrobial sulfonamide derivative and a carbonic anhydrase II inhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water.
    Halazone
  • HY-B0483
    Tioxolone
    Inhibitor 98.24%
    Tioxolone is an inhibitor of the metalloenzyme carbonic anhydrase I and has anti-acne activity.
    Tioxolone
  • HY-101087
    Benzenesulphonamide
    Inhibitor 99.51%
    Benzenesulphonamide (compound 1) is a potent carbonic anhydrase inhibitor. Benzenesulphonamide shows CA II inhibitory activity.
    Benzenesulphonamide
  • HY-142849
    Carbonic anhydrase inhibitor 2
    Inhibitor 98.40%
    Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits.
    Carbonic anhydrase inhibitor 2
  • HY-B0782R
    Acetazolamide (Standard)
    Inhibitor 99.69%
    Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
    Acetazolamide (Standard)
  • HY-163109
    Carbonic anhydrase inhibitor 16
    Inhibitor 98.00%
    Carbonic anhydrase inhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonic anhydrase hCA I and hCA II (Ki: 28.5 nM, 2.2 nM).
    Carbonic anhydrase inhibitor 16
  • HY-B0562
    Methyclothiazide
    99.76%
    Methyclothiazide is an orally active antihypertensive agent and a diuretic agent.?Methyclothiazide leads to a reduction of the vascular response to the action of endogenous vasoconstricting stimuli, such as Norepinephrine (HY-13715).?Methyclothiazide is against voltage-dependent Ca-channel (VDCC) activity in vitro.
    Methyclothiazide
  • HY-16726
    Polmacoxib
    Inhibitor 99.70%
    Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase. Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models.
    Polmacoxib
  • HY-N0085
    Dimethylfraxetin
    Inhibitor 99.97%
    Dimethylfraxetin is a Carbonic anhydrase inhibitor, with a Ki value of 0.0097 μM.
    Dimethylfraxetin
  • HY-B1056
    Procodazole
    Inhibitor 99.73%
    Procodazole is an orally active enhancer and a non-specific active immune protector against viral and bacterial infections. Procodazole also exhibits antiparasitic activity. In addition, Procodazole is a carbonic anhydrase inhibitor with antitumor activity.
    Procodazole
  • HY-108316
    Sultiame
    Inhibitor 99.76%
    Sultiame is a carbonic anhydrase inhibitor, widely used as an antiepileptic agent.
    Sultiame
  • HY-W074975
    CL 5343
    Inhibitor ≥98.0%
    CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonic anhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells.
    CL 5343
  • HY-148135
    hCAI/II-IN-6
    Inhibitor ≥98.0%
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and >50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy.
    hCAI/II-IN-6
  • HY-149301
    hCAIX-IN-18
    Inhibitor 98.52%
    hCAIX-IN-18 (compound 30) is an inhibitor of carbonic anhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research.
    hCAIX-IN-18
  • HY-B0782S
    Acetazolamide-d3
    Inhibitor 99.95%
    Acetazolamide-d3 is deuterium labeled Acetazolamide, which is a potent carbonic anhydrase (CA) inhibitor.
    Acetazolamide-d<sub>3</sub>
  • HY-110234
    Topiramate D12
    Inhibitor 99.90%
    Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate D12
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.